Department Introduction Department Overview The Hematology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, is the most internationally influential comprehensive center for the diagnosis and treatment of hematological diseases in China, leading the construction of the diagnosis and treatment system for hematological diseases and the medical, teaching, and research work of hematology in China. The Hematology Department of Ruijin Hospital was founded in 1952, and the Shanghai Institute of Hematology was established in 1987. The Hematology Department of Ruijin Hospital is a national key discipline, a National Key Clinical Specialty in Hematology of the Ministry of Health, a key construction discipline of the "211" Project, a "985" Translational Medicine Base for Leukemia, a Shanghai "Top Priority" Key Discipline, and a Shanghai First-Class Discipline, among others. In the Fudan Edition of the "2021 China Hospital Rankings" released in November 2022, the Hematology Department of Ruijin Hospital ranked third nationwide among hematology specialties. It has comprehensive diagnostic and treatment capabilities for hematological diseases, demonstrates and promotes a high-level diagnosis and treatment system, actively undertakes hematology education and talent training, builds specialty talent echelons, and cultivates clinical technical backbone personnel. In the past 5 years, the hematology specialty outpatient volume reached more than 461,700 visits, the number of admissions and discharges exceeded 40,000, and the volume of bone marrow transplantation exceeded 900 cases, ranking first in Shanghai. The Hematology Department of Ruijin Hospital has successively become a key laboratory of Shanghai Municipality, the Ministry of Health, and the Ministry of Education. In 2001, it became the State Key Laboratory of Medical Genomics and has been rated as an excellent key laboratory for four consecutive times. In 2020, the research ward of the National Major Science and Technology Infrastructure for Translational Medicine was officially put into use. Relying on the advanced research platforms of the Shanghai Institute of Hematology and the State Key Laboratory of Medical Genomics, as well as the systematic, large-scale, and integrated National Major Science and Technology Infrastructure for Translational Medicine, it is committed to the translation of original achievements, the formation of internationally original core technologies, the realization of China's original protocols playing an international leading role, and the promotion of the standardized and normalized development of the diagnosis and treatment of hematological diseases in China. In the past 5 years, the discipline has undertaken more than 80 research projects, including those funded by the National Natural Science Foundation of China, with project funding exceeding 105.996 million yuan.